[go: up one dir, main page]

EP1906976A4 - Polymeres therapeutiques et leurs procedes d'utilisation - Google Patents

Polymeres therapeutiques et leurs procedes d'utilisation

Info

Publication number
EP1906976A4
EP1906976A4 EP06760640A EP06760640A EP1906976A4 EP 1906976 A4 EP1906976 A4 EP 1906976A4 EP 06760640 A EP06760640 A EP 06760640A EP 06760640 A EP06760640 A EP 06760640A EP 1906976 A4 EP1906976 A4 EP 1906976A4
Authority
EP
European Patent Office
Prior art keywords
methods
therapeutic polymers
therapeutic
polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06760640A
Other languages
German (de)
English (en)
Other versions
EP1906976A2 (fr
Inventor
William G Turnell
Zaza D Gomurashvili
Ramaz Katsarava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivas LLC
Original Assignee
Medivas LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivas LLC filed Critical Medivas LLC
Publication of EP1906976A2 publication Critical patent/EP1906976A2/fr
Publication of EP1906976A4 publication Critical patent/EP1906976A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G71/00—Macromolecular compounds obtained by reactions forming a ureide or urethane link, otherwise, than from isocyanate radicals in the main chain of the macromolecule
    • C08G71/04—Polyurethanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/12—Polyester-amides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Polyamides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP06760640A 2005-06-03 2006-06-02 Polymeres therapeutiques et leurs procedes d'utilisation Withdrawn EP1906976A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68757005P 2005-06-03 2005-06-03
US75917906P 2006-01-13 2006-01-13
PCT/US2006/021395 WO2006132950A2 (fr) 2005-06-03 2006-06-02 Polymeres therapeutiques et leurs procedes d'utilisation

Publications (2)

Publication Number Publication Date
EP1906976A2 EP1906976A2 (fr) 2008-04-09
EP1906976A4 true EP1906976A4 (fr) 2011-11-09

Family

ID=37498935

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06760640A Withdrawn EP1906976A4 (fr) 2005-06-03 2006-06-02 Polymeres therapeutiques et leurs procedes d'utilisation

Country Status (5)

Country Link
EP (1) EP1906976A4 (fr)
JP (1) JP2008542393A (fr)
AU (1) AU2006255262A1 (fr)
CA (1) CA2610745A1 (fr)
WO (1) WO2006132950A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US7273469B1 (en) 2003-12-31 2007-09-25 Advanced Cardiovascular Systems, Inc. Modified needle catheter for directional orientation delivery
JP5192384B2 (ja) 2005-09-22 2013-05-08 メディバス エルエルシー ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法
US8445627B2 (en) * 2006-03-24 2013-05-21 Medivas, Llc Alkylene-dicarboxylate-containing biodegradable poly(ester-amides) and methods of use
WO2007133616A2 (fr) * 2006-05-09 2007-11-22 Medivas, Llc Polymères hydrosolubles biodégradables
US20080200377A1 (en) * 2007-02-16 2008-08-21 Trollsas Mikael O Polymer particles
EP2227223A4 (fr) * 2007-12-06 2013-11-27 Medivas Llc Compositions polymères à base d'oligo-éthylène glycol et procédé d'utilisation
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9963549B2 (en) 2011-06-23 2018-05-08 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
WO2016097297A1 (fr) 2014-12-18 2016-06-23 Dsm Ip Assets B.V. Système d'administration de médicament pour administration de médicaments sensibles aux acides
US10772964B2 (en) 2015-06-23 2020-09-15 Phagelux (Canada), Inc. Composition comprising a polymer and a bioactive agent and method of preparing thereof
CN110804175B (zh) * 2019-11-08 2021-05-14 中国科学院理化技术研究所 一种交替结构抗菌聚氨基酸衍生物或共聚物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020015720A1 (en) * 2000-01-11 2002-02-07 Ramaz Katsarava Polymer blends as biodegradable matrices for preparing biocomposites
US20020071822A1 (en) * 2000-07-27 2002-06-13 Uhrich Kathryn E. Therapeutic polyesters and polyamides
EP1945682A2 (fr) * 2005-10-21 2008-07-23 Medivas, LLC Polymeres de poly(ester-uree) et leurs procedes d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249050A1 (en) * 2000-01-11 2001-07-24 Intralytix, Inc. Reduction in bacterial colonization by administering bacteriophage compositions
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
EP1549253A4 (fr) * 2002-09-26 2010-11-03 Endovascular Devices Inc Appareil et procede de distribution de mitomycine au moyen d'un dispositif medical d'elution biocompatible implantable

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020015720A1 (en) * 2000-01-11 2002-02-07 Ramaz Katsarava Polymer blends as biodegradable matrices for preparing biocomposites
US20020071822A1 (en) * 2000-07-27 2002-06-13 Uhrich Kathryn E. Therapeutic polyesters and polyamides
EP1945682A2 (fr) * 2005-10-21 2008-07-23 Medivas, LLC Polymeres de poly(ester-uree) et leurs procedes d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAURO A.M CARAI ET AL: "Central effects of 1,4-butanediol are mediated by GABAB receptors via its conversion into [gamma]-hydroxybutyric acid", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 441, no. 3, 1 April 2002 (2002-04-01), pages 157 - 163, XP055008078, ISSN: 0014-2999, DOI: 10.1016/S0014-2999(02)01502-9 *
SCHMELTZER R C ET AL: "Synthesis and cytotoxicity of salicylate-based poly(anhydride esters)", BIOMACROMOLECULES, ACS, WASHINGTON, DC, US, vol. 6, no. 1, 1 January 2005 (2005-01-01), pages 359 - 367, XP002482507, ISSN: 1525-7797, [retrieved on 20041126], DOI: 10.1021/BM049544+ *
WOO G L Y ET AL: "Synthesis and characterization of a novel biodegradable antimicrobial polymer", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 12, 1 June 2000 (2000-06-01), pages 1235 - 1246, XP004195834, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(00)00003-X *

Also Published As

Publication number Publication date
AU2006255262A1 (en) 2006-12-14
WO2006132950A3 (fr) 2007-06-14
EP1906976A2 (fr) 2008-04-09
JP2008542393A (ja) 2008-11-27
CA2610745A1 (fr) 2006-12-14
WO2006132950A2 (fr) 2006-12-14

Similar Documents

Publication Publication Date Title
IL182734A0 (en) 4-aminotetracyclines and methods of use thereof
IL176958A0 (en) Compounds and methods of use
EP2091588A4 (fr) Dispositif cardiaque et ses procédés d'utilisation
GB0625659D0 (en) Therapeutic compounds and their use
IL190055A0 (en) Quinolines and their therapeutic use
EP1942815A4 (fr) Outil d'installation medicale et procedes d'emploi
EP1879515A4 (fr) Implants osteosynthetiques et procedes d'utilisation et de fabrication
IL180978A0 (en) Isoindoline compounds and methods of their use
EP1957145A4 (fr) Reseaux de microaiguilles et leurs methodes d'utilisation
PL1815247T3 (pl) Terapeutyczne zastosowanie inhibitorów transferazy farnezylowej i metody kontroli ich skuteczności
EP1827391A4 (fr) Formes posologiques et procedes d'utilisation de celles-ci
IL186342A0 (en) Spirocyclic heterocycic derivaives and methods of their use
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
GB0421164D0 (en) Medical devices and methods of making medical devices
EP1742971A4 (fr) Polymeres chitineux n-acyles et procedes d'utilisation de ces derniers
EP1906976A4 (fr) Polymeres therapeutiques et leurs procedes d'utilisation
EP1789047A4 (fr) Procede pour traiter des maladies au moyen de nalmefene et de ses analogues
EP1838288A4 (fr) Materiels et procedes therapeutiques
EP1812451A4 (fr) Composes et methodes d'utilisation de ces composes
EP2097085A4 (fr) Matériaux et procédés thérapeutiques
GB0407382D0 (en) Therapeutic methods and means
GB0426196D0 (en) Methods of treatment
IL185575A0 (en) Benzoxazocines and their therapeutic use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071228

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20111011

RIC1 Information provided on ipc code assigned before grant

Ipc: C08L 75/02 20060101ALI20111005BHEP

Ipc: A61K 31/785 20060101ALI20111005BHEP

Ipc: C08L 77/00 20060101AFI20111005BHEP

Ipc: A61K 9/16 20060101ALI20111005BHEP

Ipc: A61K 9/51 20060101ALI20111005BHEP

Ipc: C08G 18/10 20060101ALI20111005BHEP

Ipc: C12N 15/88 20060101ALI20111005BHEP

Ipc: A61K 47/34 20060101ALI20111005BHEP

Ipc: C08G 69/44 20060101ALI20111005BHEP

Ipc: C08L 77/12 20060101ALI20111005BHEP

Ipc: A61K 47/48 20060101ALI20111005BHEP

Ipc: A61K 48/00 20060101ALI20111005BHEP

Ipc: A61K 9/50 20060101ALI20111005BHEP

Ipc: C07K 16/28 20060101ALI20111005BHEP

Ipc: A61K 9/107 20060101ALI20111005BHEP

Ipc: A61F 2/00 20060101ALI20111005BHEP

Ipc: C08L 75/06 20060101ALI20111005BHEP

Ipc: C08L 75/04 20060101ALI20111005BHEP

Ipc: A61L 31/00 20060101ALI20111005BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120508